Clinical Trials › NCT05338450
RecruitingPhase 3
Clemastine Fumarate as Remyelinating Treatment in Internuclear Ophthalmoparesis and Multiple Sclerosis
Sponsored by Amsterdam UMC, location VUmc
Interested in joining? Eligibility criteria and contact info are on ClinicalTrials.gov.
View on ClinicalTrials.gov 80
Target enrollment
Aug 2022
Start date
Dec 2027
Expected completion
Interventions / Treatments
Clemastine FumaratePlacebo
Conditions studied
Multiple Sclerosis
Trial locations
U.S. site locations haven't been posted yet for this trial. Check ClinicalTrials.gov for the latest contact and location info.
More Phase 3 trials
Browse all Phase 3 MS trialsThe app
Check out the MS Buddy app
Track symptoms, monitor wellness, and stay on top of your MS care. It’s free, with no ads. Built by people living with MS.